Verition Fund Management
APTO

Verition Fund Management’s Aptose Biosciences, Inc. APTO Stock Holding History

Verition Fund Management’s Portfolio APTO Stock Details APTO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-235
Closed -$599K – 1146
2019
Q4 		$599K Buy
+235
New +$306K 0.01% 609

Other funds holding APTO

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
DS
DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
CA
Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PM
Precept Management Dallas, Texas $126M AUM 36.77% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Verition Fund Management's APTO Position: Q1 2020 in Review

Verition Fund Management sold out of Aptose Biosciences, Inc. (APTO) in Q1 2020, closing a stake of 235 shares — an estimated $599K sold.

Verition Fund Management first reported a position in APTO in Q4 2019 and held it in 1 quarter. The position peaked at $599K in Q4 2019. 51 funds tracked by Wall St. Rank hold APTO as of Q1 2020.

  • Verition Fund Management reported no remaining Aptose Biosciences, Inc. position as of Q1 2020 after selling out during the quarter.
  • Verition Fund Management sold 235 Aptose Biosciences, Inc. shares in Q1 2020, an estimated $599K.
  • Verition Fund Management first reported a position in Aptose Biosciences, Inc. in Q4 2019 and held it in 1 quarter.
  • Verition Fund Management's Aptose Biosciences, Inc. position peaked at $599K in Q4 2019.
  • 51 funds tracked by Wall St. Rank held Aptose Biosciences, Inc. as of Q1 2020.

Based on Verition Fund Management's 13F filing for Q1 2020, filed 15 May 2020.